Stockreport

HC Wainwright Affirms Buy Rating on Lineage Cell Therapeutics Inc. (LCTX) amid Type 1 Diabetes Push [Yahoo! Finance]

Lineage Cell Therapeutics, Inc.  (LCTX) 
PDF reiterated a ‘Buy' rating on the stock and a $9 price target, buoyed by the stock's impressive run year to date. HC Wainwright Affirms Buy Rating on Lineage Cell Thera [Read more]